Member Info for Dunnieboy

USA took delivery of 300,000 doses this month and negotiating to buy another 600,000, at $2100 a dose these are big numbers.
The administration also expects to allocate about another 300,000 courses of GlaxoSmithKline Plc’s monoclonal antibody treatment by the end of January -- the only such drug they think has shown effectiveness against omicron -- and is in talks to purchase 600,000 more, the officials said.

A new Covid drug designed to reduce the risk of vulnerable patients needing hospital treatment will be available on the NHS from today.
Sotrovimab is a monoclonal antibody given as a transfusion to transplant recipients, cancer patients and other high-risk groups.
If given quickly after symptoms develop it is should help prevent people from falling seriously ill with the disease.
Initial tests suggest it should still work against the Omicron variant.
"These new drugs have an important role to play," said Prof Steven Powis, the national medical director of NHS England.
"If you test positive and are at high risk then we will be contacting you, and, if eligible, you will be able to get access to these new treatments."

Defo TR, initially they made 2.4m doses which is charged out at $2100, GSK & Vir are ramping up the next production run which could be 10m plus especially now it is a intramuscular jab as opposed to the original version being intravenous which is much more time & labour intensive.

TR64 brill

Regeneron & Lilly’s mabs efficacy fell dramatically when tested against Omicron, GSK & Vir’s Sotrovimab retains its efficacy & now stands as ‘best in class’.
Buy Vir!

Preclinical Data Highlight the Significant Antigenic Shift of the Omicron SARS-CoV-2 Variant and its Effect on the Neutralizing Activity of Monoclonal Antibodies, Convalescent Antibodies and Vaccine-Elicited Antibodies
12/14/21 at 4:39 PM EST
PDF Version
– Data demonstrate sotrovimab, developed by Vir in conjunction with GlaxoSmithKline, continues to retain in vitro neutralizing activity against all tested variants of concern, including Omicron –

SAN FRANCISCO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic shift of the new SARS-CoV-2 Omicron variant (B.1.1.529). A significant reduction in plasma neutralizing activity

TR64, where does it say about KKR shorting Vir & Laxo?

Glaxo confirmed that their monoclonal antibody treatment works against all mutations of Omicron.
And a further contract has been signed to supply Singapore.
TR64 was ahead of the game on this one.

Daily Mail reports that the success of GSK/Vir’s monoclonal antibody Sotrovimab against Omicron is a ‘shot in the arm’ for Walmsley,.
Vir is being mooted as a takeover target for Glaxo who currently own 8/10% of Vir’s stock.

TR6, brilliant news for us, VIir Bio is up 16% pre-market on this news.

USA ordered $1bn worth only last week, multiple other countries have also placed orders, this Sotrovimab is $2100 a shot.

??

Sotrovimab GSK/Vir’s Covid monoclonal antibody is the only treatment that remains effective against the New strain of Covid19, Vir is up 15% pre-market Nasdaq.
GSK owns 8/10% of Vir Biotechnology.
Needham’s have just raised the Vir pt from $135 to $200.

Lost me there!!!

Great article on ‘Seeking Alpha’ about Glaxo/Vir’s monoclonal antibody therapy Sotrovimab, it’s saying it has stood up to all mutations so far, whilst vaccines are going to take up to three months to modify & a lot longer manufacture & deliver.
Vir Biotechnology trades on the Nasdaq and SAlpha believes it could shoot up.

Just to clarify GSK owns roughly 8% of Vir Bio’s stock.

Vir Biotechnology was up 12% today after Merck’s Covid drug was found to have only 30% efficacy in the latest trials, Glaxo/Vir’s antibody therapy Sotrovimab/Xevudy stands up against the latest mutation with 85% efficacy.

for the supply of Sotrovimab, initial value of $1bn.

I thought the results were due out at 7am

https://endpts.com/gsk-and-vir-turn-to-us-for-distribution-as-covid-19-mab-treatment-nears-blockbuster-status/